Curcumin C3 Complex® Subject of New Control Trial

April 26, 2010

1 Min Read
SupplySide Supplement Journal logo in a gray background | SupplySide Supplement Journal

EAST WINDSOR, N.J.Curcumin, derived from the spice turmeric (curry powder), is a major staple in Indian lifestyle and has been shown to suppress survival, proliferation, invasion, angiogenesis and metastasis of colon cancer cells. The potential role of curcumin as a therapeutic intervention warrants further investigation, and has prompted the St. George Hospital to commence a double blind, randomized, control trial using higher dosages of Sabinsas Curcumin C3 Complex® in a larger cohort of patients.

Curcumin C3 Complex has been the subject of many studies including, Curcumin and colorectal cancer: Add spice to your life published in the Current Colorectal Cancer Reports (2009); and The Division of Hematology/Oncology, Department of Internal Medicine and Comprehensive Cancer Center, University of Michigan used Sabinsas Curcumin C3 Complexand BioPerine® combination in a clinical trial aimed at reducing stem cell number and inhibiting its self-renewal as part of their treatment protocols: Targeting breast stem cells with the cancer preventive compounds curcumin and piperine.

 

 

Subscribe for the latest consumer trends, trade news, nutrition science and regulatory updates in the supplement industry!
Join 37,000+ members. Yes, it's completely free.

You May Also Like